Zymeworks
Computational biotechnology company that is focused on optimizing therapeutic antibodies and other protein-based therapeutics.
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 32 % | (50 %) | 2008 % | (82 %) | - | 42 % | 41 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (481 %) | (808 %) | 32 % | (157 %) | (121 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (464 %) | (794 %) | 30 % | (156 %) | (161 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 433 % | 749 % | 51 % | 189 % | 176 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Zymeworks is a biopharmaceutical company focused on developing multifunctional therapeutics for patients with difficult-to-treat cancers and other serious diseases. Operating in the biotechnology sector, Zymeworks serves healthcare providers, research institutions, and pharmaceutical companies. The company leverages its proprietary technology platforms to create antibody-drug conjugates and multispecific antibody therapeutics. Zymeworks generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, as well as through the commercialization of its own therapeutic products. The company's integrated R&D engine, from target selection to pivotal studies, is driven by a team of world-class researchers dedicated to discovering, developing, and commercializing novel agents globally.
Keywords: biopharmaceutical, multifunctional therapeutics, antibody-drug conjugates, multispecific antibodies, biotechnology, cancer treatment, serious diseases, R&D, partnerships, commercialization.